Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Brokerages

Illumina, Inc. (NASDAQ:ILMNGet Free Report) has received a consensus recommendation of “Hold” from the twenty-one analysts that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $157.62.

Several research firms have weighed in on ILMN. Royal Bank of Canada cut their target price on Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a research note on Monday. Evercore ISI cut their target price on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. Jefferies Financial Group began coverage on Illumina in a research note on Monday, June 3rd. They issued a “hold” rating and a $115.00 price target for the company. StockNews.com began coverage on Illumina in a report on Sunday. They issued a “buy” rating for the company. Finally, OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th.

Get Our Latest Stock Analysis on Illumina

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Trivant Custom Portfolio Group LLC lifted its stake in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after purchasing an additional 125 shares during the last quarter. VisionPoint Advisory Group LLC lifted its position in Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares during the period. Wetzel Investment Advisors Inc. bought a new position in Illumina during the fourth quarter valued at approximately $37,000. Massmutual Trust Co. FSB ADV lifted its position in Illumina by 86.8% during the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after purchasing an additional 132 shares during the period. Finally, Gradient Investments LLC raised its position in Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after acquiring an additional 225 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Down 0.2 %

Shares of NASDAQ:ILMN opened at $105.28 on Thursday. The company has a market capitalization of $16.77 billion, a P/E ratio of -12.92 and a beta of 1.15. Illumina has a 1 year low of $89.00 and a 1 year high of $195.64. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The business’s 50 day simple moving average is $110.95 and its 200 day simple moving average is $126.99.

Illumina (NASDAQ:ILMNGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.08 earnings per share. On average, research analysts anticipate that Illumina will post 0.98 EPS for the current fiscal year.

Illumina Company Profile

(Get Free Report

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

See Also

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.